Overview

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors

Status:
Recruiting

Trial end date:
2025-02-01

Target enrollment:

Participant gender:

Summary

This study aims to test the safety, tolerability, and preliminary anti-tumor activity of BGB-A3055, either alone or in combination with Tislelizumab in participants with advanced or metastatic solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

BeiGene

Treatments:

Tislelizumab